- Home
- INSW vs AZTA Comparison
INSW vs AZTA Comparison
Compare INSW & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- AZTA
- Stock Information
- Founded
- INSW 1999
- AZTA 1978
- Country
- INSW United States
- AZTA United States
- Employees
- INSW N/A
- AZTA N/A
- Industry
- INSW Semiconductors
- AZTA Industrial Machinery/Components
- Sector
- INSW Technology
- AZTA Technology
- Exchange
- INSW Nasdaq
- AZTA Nasdaq
- Market Cap
- INSW 1.7B
- AZTA 1.8B
- IPO Year
- INSW N/A
- AZTA 1995
- Fundamental
- Price
- INSW $33.09
- AZTA $34.64
- Analyst Decision
- INSW Strong Buy
- AZTA Buy
- Analyst Count
- INSW 3
- AZTA 4
- Target Price
- INSW $60.00
- AZTA $58.75
- AVG Volume (30 Days)
- INSW 823.2K
- AZTA 721.0K
- Earning Date
- INSW 05-07-2025
- AZTA 05-07-2025
- Dividend Yield
- INSW 15.52%
- AZTA N/A
- EPS Growth
- INSW N/A
- AZTA N/A
- EPS
- INSW 8.38
- AZTA N/A
- Revenue
- INSW $951,613,000.00
- AZTA $662,108,000.00
- Revenue This Year
- INSW N/A
- AZTA N/A
- Revenue Next Year
- INSW $2.65
- AZTA $5.44
- P/E Ratio
- INSW $3.96
- AZTA N/A
- Revenue Growth
- INSW N/A
- AZTA 5.36
- 52 Week Low
- INSW $31.70
- AZTA $33.33
- 52 Week High
- INSW $65.94
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- INSW 41.01
- AZTA 28.59
- Support Level
- INSW $33.56
- AZTA $35.88
- Resistance Level
- INSW $34.92
- AZTA $38.57
- Average True Range (ATR)
- INSW 1.10
- AZTA 1.77
- MACD
- INSW 0.03
- AZTA -0.01
- Stochastic Oscillator
- INSW 26.56
- AZTA 18.03
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.